Molecular Partners hopes for COVID-19 rebound after eye drug failure

This post was originally published on this site

ZURICH, June 26 (Reuters) – Molecular Partners aims to treat patients with its COVID-19 drug candidate this year, Chief Executive Patrick Amstutz said on Friday, as the Swiss company hopes it will help it recover from the failure of its eye drug abicipar.

Click here to read full article